St Asaph - November 2015 Dr Richard Anderson Consultant Cardiologist Senior Lecturer University Hospital of Wales, Cardiff, UK Wales Audit Data 2014-15.

Slides:



Advertisements
Similar presentations
Northeast Georgia Heart Center The Critical Importance of Cath Lab Visits! J. Jeffrey Marshall, MD Vice President Society for Cardiovascular Angiography.
Advertisements

Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany BSIC, Manchester, September 15, 2006.
PPCI – National Update NCBC Workshop Jim McLenachan, National Clinical Lead for PPCI, NHS Improvement, England. London, 24 th November, NCBC Annual.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
WG Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
What Do We Mean By Quality In PCI Institutional Requirements Dr Bernard Prendergast John Radcliffe Hospital, Oxford.
PCI For MVD: Complete vs Partial Revascularization --Partial More Realistic in Most Patients Yuejin Yang MD, PhD, FACC Cardiovascular Institute and Fu-Wai.
Ischemic heart disease Basic Science 3/15/06. All of the following concerning coronary artery anatomy are correct except: The left main coronary artery.
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Qu Xinkai Shanghai Chest Hospital Shanghai Jiaotong University Value of comprehensive cardiac evaluation using MSCT in patients with CTO.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
DGH v Tertiary Intervention Is there really a conflict? “The BCIS Perspective” Dr Martyn Thomas Kings College Hospital BCIS President.
Is avoidable mortality a good measure of the quality of hospital care? Dr Helen Hogan Clinical Senior Lecturer in Public Health London School of Hygiene.
High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.
PCI v CABG Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Are we doing enough PCI in the elderly ? Rosie Swallow Dorset Heart Centre Royal Bournemouth Hospital.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Total Occlusion Study of Canada (TOSCA-2) Trial
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
Interesting Case Presentation
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Tarek Abou Ghazala, MD, FACC, FSCAI
CRT 2017 Interventional Challenging Case Anterior ST- Elevation Myocardial Infarction Resulting From Acute Occlusion of Left Internal Mammary Artery Graft.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Treating CTOs Is there evidence based data?
Should we Use OCT in STEMI Patients?
Meruzhan Saghatelyan, MD, Interventional cardiologist
Copyright © 2005 American Medical Association. All rights reserved.
How to Build Your Own CTO PCI Program
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 YSBYTY GLAN CLWYD (YGC) MDT.
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Fractional Flow Reserve Workshop
Preventing Thrombotic Complications in ACS: State of the Art
Recurrent Angina: New Tools for an Old Problem
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
European Heart Association Journal 2007 April
Section 5: Intervention and drug therapy
European Society of Cardiology 2003
Invasive versus conservative treatment in unstable coronary syndromes
Preventive Angioplasty in Myocardial Infarction Trial
Published in the European Heart Journal
Primary PCI Monitoring Performance
Primary PCI Monitoring Performance
EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.
What oral antiplatelet therapy would you choose?
Ischemic Postconditioning
DEScover: One-Year Clinical Results
Atlantic Cardiovascular Patient Outcomes Research Team
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

St Asaph - November 2015 Dr Richard Anderson Consultant Cardiologist Senior Lecturer University Hospital of Wales, Cardiff, UK Wales Audit Data Stable Angina PCI and CTO

Definitions Stable PCI – all elective PCI excluding acute STEMI/NSTEMI – Can include OP staged post STEMI patients Four PCI centres – UHW - Cardiff – MH - Swansea – NWCC - Glan Clwyd – RGH - Newport Period 1 st Apr 2014 to 31 st Mar 2015 UHW + GWE 2014 calender year Comparison with BCIS UK 2014 PCI data

Thank you for the data Shantu Bundhoo Paul Das Steve Dorman

PCI Numbers by Centre

UHW – 26% MOR % YGC – 29.5% GWE – 45.5%

Radial Access Site by Centre All indications

Optical Coherence Tomography Ruptured thin cap atheromatous plaque Coronary Intramural haematoma

Procedural techniques by centre All PCI Indications

Death or need for Emergency CABG (%) Stable PCI Only 11

Chronic Total Occlusions (CTO’s) A chronic total occlusion (CTO) is defined - complete occlusion of the coronary vessel with TIMI 0 flow, present for an (estimated) duration of ≥3 months. A = Occluded Vessel F = Restablishing antegrade blood flow B = Collateral fiiling of distal coronary bed

Reduction in ischemic burden Enable completeness of revascularization Improvement of symptoms Improvement in LV function Reduced predisposition to arrhythmic events and ischemic events Avoidance of procedures and reduced medications Survival benefit Chronic Total Occlusions (CTO’s) Why do them?

What are the downsides? Technical and procedural challenges (radiation, contrast etc...) Misperceptions regarding viability, collateral flow Uncertainty regarding which patients may benefit Concern for complications in patients who may not derive much/any clinical benefit Centre – long cases and take up valuable cath lab session (1-2 hours+)

CTO Numbers by Centre

YGC – 12.4% MOR – 19% UHW – 18% GWE – 16.5%

No reported mortalities in the Welsh centres for the financial year 2014/5

UHW

GWE

Glan Clwyd YGC

MOR

Operator Specific data

Summary Stable PCI numbers PMP in Wales below the national UK average Outcomes are V good Contemporaneous adjunctive techniques CTO numbers are in line with the UK volume – Subspecialization is advised per centre to maximize expertise and improve patient outcomes.

Many thanks